MERS coronavirus: Data gaps for laboratory preparedness

被引:40
作者
de Sousa, Rita [1 ,2 ]
Reusken, Chantal [1 ,3 ]
Koopmans, Marion [1 ,3 ]
机构
[1] Natl Inst Publ Hlth & Environm, Ctr Infect Dis Res Diagnost & Screening, Div Virol, NL-3720 BA Bilthoven, Netherlands
[2] European Ctr Dis Control, European Programme Publ Hlth Microbiol Training E, Stockholm, Sweden
[3] Erasmus MC, Dept Virosci, Rotterdam, Netherlands
关键词
Middle East Respiratory Syndrome; Coronavirus; Laboratory preparedness; SARS; RESPIRATORY SYNDROME CORONAVIRUS; MIDDLE-EAST; SARS-CORONAVIRUS; FAMILY CLUSTER; ANTIBODIES; INFECTIONS; PNEUMONIA; NL63; SYMPTOMS; CHILDREN;
D O I
10.1016/j.jcv.2013.10.030
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Since the emergence of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012, many questions remain on modes of transmission and sources of virus. In outbreak situations, especially with emerging organisms causing severe human disease, it is important to understand the full spectrum of disease, and shedding kinetics in relation to infectivity and the ability to transmit the microorganism. Laboratory response capacity during the early stages of an outbreak focuses on development of virological and immunological methods for patient diagnosis, for contact tracing, and for epidemiological studies into sources, modes of transmission, identification of risk groups, and animal reservoirs. However, optimal use of this core public health laboratory capacity requires a fundamental understanding of kinetics of viral shedding and antibody response, of assay validation and of interpretation of test outcomes. We reviewed available data from MERS-CoV case reports, and compared this with data on kinetics of shedding and immune response from published literature on other human coronaviruses (hCoVs). We identify and discuss important data gaps, and biases that limit the laboratory preparedness to this novel disease. Public health management will benefit from standardised reporting of methods used, details of test outcomes by sample type, sampling date, in relation to symptoms and risk factors, along with the currently reported demographic, clinical and epidemiological findings. (C) 2013 Elsevier B. V. All rights reserved.
引用
收藏
页码:4 / 11
页数:8
相关论文
共 55 条
  • [51] Coronavirus Diversity, Phylogeny and Interspecies Jumping
    Woo, Patrick C. Y.
    Lau, Susanna K. P.
    Huang, Yi
    Yuen, Kwok-Yung
    [J]. EXPERIMENTAL BIOLOGY AND MEDICINE, 2009, 234 (10) : 1117 - 1127
  • [52] Clinical and molecular epidemiological features of coronavirus HKU1-associated community-acquired pneumonia
    Woo, PCY
    Lau, SKP
    Tsoi, HW
    Huang, Y
    Poon, RWS
    Chu, CM
    Lee, RA
    Luk, WK
    Wong, GKM
    Wong, BHL
    Cheng, VCC
    Tang, BSF
    Wu, AKL
    Yung, RWH
    Chen, HL
    Guan, Y
    Chan, KH
    Yuen, KY
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2005, 192 (11) : 1898 - 1907
  • [53] World Health Organization, 2013, MERS COV SUMM LIT UP
  • [54] World Health Organization, 2013, REV INT CAS DEF REP
  • [55] Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
    Zaki, Ali Moh
    van Boheemen, Sander
    Bestebroer, Theo M.
    Osterhaus, Albert D. M. E.
    Fouchier, Ron A. M.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2012, 367 (19) : 1814 - 1820